ENROLLMENT/ PRIOR AUTHORIZATION FORM

Fax: 1-888-335-3264 Phone: 1-855-EYLEA4U (1-855-395-3248), Option 4 www.EYLEA4Ueportal.com



Section 1.1: Support Requested (chec	k all that apply)			•	
 Benefits Investigation Appeals Support Alternate Coverage Referral Prior Author 		Patient Assistance Program	')		
Section 2.1: Patient Information	Detient Contact Infor	mation Attached			
First Name: Middle Initial: _	Last Name:	SSN:	Gender: 🗆 Male 🗆 Female	е	
Date of Birth: Home Phone:				-	
Address:	City:		State: ZIP:	-	
Section 2.2: Patient Insurance Inform			/ or private insurance)?	٦	
		# (Medicare/Medicare Advantage			
Primary Insurance (If copy of insurance card atta		Secondary Insurance (If copy of insurance card attached, check here Name:			
Name: Phone:					
Insured Name:					
Policy Number:					
Employer:		Employer:		_	
Group Number:		Group Number:		_	
Section 2.3: Patient Authorization an	d Certification	Date:			
I have read and agree to the Authorization to Disclose/Use Health Information in 6.1		I have read and agree to enroll in EYLEA4U [®] and to the Patient Certification included in Section 6.3			
Patient Signature:			′e:	-	
Section 3.1: Treatment Information/P Dispense: Vial(s) NDC: 61755-005-02 PFS SIG: Inject 2 mg (0.05 mL) every 4 weeks (mo SIG: Inject 2 mg (0.05 mL) every 12 weeks (3 SIG: Inject 2 mg (0.05 mL) every 4 weeks (mo SIG: Inject 2 mg (0.05 mL) every 4 weeks (mo	(s) NDC: 61755-005-01 onthly) for the first 3 inj months) after one year onthly) for the first 5 inj	of effective therapy with regular	nL) once every 8 weeks assessment	_	
Section 4.1: Prescribing Physician Info	ormation				
Site of Service: Physician Office Hospita				_	
Physician Name:				-	
Physician Specialty: Physician's St Lic#:	Address:	City:	State: ZIP:	-	
Physician's Tax ID#:	Physicial	n's National Provider Identifier (N	PI):	_	
Section 4.2: Office Contact Informati					
Primary Office Contact:	Phone:	Fax:	E-Mail:	_	
Section 4.3: Physician Certification Must be signed by the physician for all Enrollment Form submissions, including e-Portal.					
My signature certifies the following: (i) that the person named on this Enrollment Form is my patient, (ii) that I have obtained his/her written authorization and certification under Section 2.3 of this form, (iii) that to the best of my knowledge the information, if applicable, under Section 6.2 of this form is accurate and complete, (iv) that I will retain in my files the complete patient-executed Enrollment Form, and (v) that upon request, I will promptly provide a copy of this patient-executed Enrollment Form on file to EYLEA4U.					
My signature below certifies that the person name is complete and accurate, and that EYLEA receive With regard to any patient eligible for patient ass for sale, trade, or barter and EITHER no claim for Medicare, Medicaid, or any third-party payer OR I deemed uninsured after a claim was submitted. I contacting me by fax, phone, mail, or email to cor that Regeneron Pharmaceuticals, Inc. may revise, Pharmaceuticals, Inc. and its representatives and and I appoint the EYLEA4U program solely to cor	d in response to this app istance through the EYL reimbursement of either will provide appropriate consent to Regeneron P firm receipt of EYLEA c change, or terminate an contractors to forward t	blication is only for the use of EYL EA4U program, I acknowledge th r EYLEA or related medical procers e denial and appeals documentatin harmaceuticals, Inc. and its affiliat or provide additional information a y program services at any time w his prescription to a dispensing p	EA for the patient named on this form. at this medication will not be offered dures and services will be submitted to on to support requests for patients who are tes, representatives, agents, and contractors about EYLEA or the EYLEA4U program and ithout notice to me. I authorize Regeneron harmacy on behalf of myself and my patient.		
Physician Signature:			Date:	_	
Signature required; this form cannot be pre-	ocessed without an origi	nal or stamped signature.			

Please see full Prescribing Information available at www.EYLEA.com.

Patient Name _ Middle Initial: _____ Last Name: _ First Name: Section 5.1: Diagnosis (Select one as a primary diagnosis. For additional diagnoses please indicate on Page 3) Wet Age-related Macular Degeneration (Wet AMD) Exudative age-related macular degeneration **Right eye** Left eye Bilateral Unspecified eye □ H35.3211 □ H35.3221 H35.3231 □ H35.3291 With active choroidal neovascularization With inactive choroidal neovascularization □ H35.3212 □ H35.3222 □ H35.3232 □ H35.3292 With inactive scar 🗆 H35.3213 □ H35.3223 □ H35.3233 🗆 H35.3293 Stage unspecified □ H35.3210 □ H35.3220 □ H35.3230 □ H35.3290 Macular Edema following Retinal Vein Occlusion (MEfRVO) **Central retinal vein occlusion Right eye** Left eye Bilateral Unspecified eye With macular edema 🗆 H34.8110 **H34.8120** 🗆 H34.8130 **H34.8190** Tributary (branch) retinal vein occlusion **Right eye** Left eye Bilateral Unspecified eye With macular edema **H34.8310** □ H34.8320 □ H34.8330 □ H34.8390 **Diabetic Macular Edema (DME)** Diabetes mellitus due to underlying condition with... **Right eye** Left eye Bilateral Unspecified eye Mild nonproliferative diabetic retinopathy with macular edema **E08.3211 E08.3212 E08.3213 E08.3219** Moderate nonproliferative diabetic retinopathy with macular edema E08.3311 **E08.3312 E08.3313** E08.3319 Severe nonproliferative diabetic retinopathy with macular edema **E08.3411 E08.3412 E08.3413 E08.3419** Proliferative diabetic retinopathy with macular edema **E08.3511 E08.3512 E08.3513 E08.3519** Unspecified diabetic retinopathy with macular edema **E08.311** Drug or chemical induced diabetes mellitus with... Bilateral **Right eye** Left eye Unspecified eye Mild nonproliferative diabetic retinopathy with macular edema **E09.3211 E09.3212 E09.3213 E09.3219** Moderate nonproliferative diabetic retinopathy with macular edema **E09.3311 E09.3312 E09.3313 E09.3319** Severe nonproliferative diabetic retinopathy with macular edema **E09.3411 E09.3412 E09.3413 E09.3419** Proliferative diabetic retinopathy with macular edema **E09.3511 E09.3512** E09.3513 E09.3519 Unspecified diabetic retinopathy with macular edema **E09.311** Type 1 diabetes mellitus with... **Right eye** Left eye Bilateral Unspecified eye Mild nonproliferative diabetic retinopathy with macular edema E10.3211 **E10.3212** E10.3213 E10.3219 Moderate nonproliferative diabetic retinopathy with macular edema E10.3311 E10.3312 E10.3313 E10.3319 Severe nonproliferative diabetic retinopathy with macular edema E10.3411 E10.3412 E10.3413 E10.3419 Proliferative diabetic retinopathy with macular edema E10.3511 **E10.3512** E10.3513 E10.3519 Unspecified diabetic retinopathy with macular edema E10.311 Type 2 diabetes mellitus with... Bilateral **Right eye** Left eye Unspecified eye Mild nonproliferative diabetic retinopathy with macular edema E11.3211 E11.3212 **E11.3213 E11.3219** 🗆 E11.3312 Moderate nonproliferative diabetic retinopathy with macular edema 🗆 E11.3311 E11.3313 E11.3319 Severe nonproliferative diabetic retinopathy with macular edema **E11.3411** E11.3412 E11.3413 E11.3419 Proliferative diabetic retinopathy with macular edema E11.3511 E11.3512 E11.3513 E11.3519 Unspecified diabetic retinopathy with macular edema 🗆 E11.311

Other specified diabetes mellitus with	Right eye	Left eye	Bilateral	Unspecified eye
Mild nonproliferative diabetic retinopathy with macular edema	🗆 E13.3211	🗆 E13.3212	🗆 E13.3213	🗆 E13.3219
Moderate nonproliferative diabetic retinopathy with macular edema	🗆 E13.3311	🗆 E13.3312	🗆 E13.3313	🗆 E13.3319
Severe nonproliferative diabetic retinopathy with macular edema	🗆 E13.3411	🗆 E13.3412	🗆 E13.3413	🗆 E13.3419
Proliferative diabetic retinopathy with macular edema	🗆 E13.3511	🗆 E13.3512	🗆 E13.3513	🗆 E13.3519
Unspecified diabetic retinopathy with macular edema	E13.311			

First Name: .

Secondary

Tertiary

Section 5.1: Diagnosis

Diabetic Retinopathy (DR) Diabetes mellitus due to underlying condition with... **Right eye** Left eye Bilateral Unspecified eye Mild nonproliferative diabetic retinopathy without macular edema **E08.3291 E08.3292 E08.3293 E08.3299** Moderate nonproliferative diabetic retinopathy without macular edema **E08.3391 E08.3392 E08.3393 E08.3399** Severe nonproliferative diabetic retinopathy without macular edema E08.3491 **E08.3492 E08.3493 E08.3499** Proliferative diabetic retinopathy without macular edema **E08.3591 E08.3592 E08.3593 E08.3599 E08.319** Unspecified diabetic retinopathy without macular edema Drug or chemical induced diabetes mellitus with... **Right eye** Left eye Bilateral Unspecified eye Mild nonproliferative diabetic retinopathy without macular edema E09.3291 **E09.3292 E09.3293 E09.3299** Moderate nonproliferative diabetic retinopathy without macular edema **E09.3391 E09.3392 E09.3393 E09.3399** Severe nonproliferative diabetic retinopathy without macular edema **E09.3491 E09.3492 E09.3493** E09.3499 Proliferative diabetic retinopathy without macular edema **E09.3591 E09.3592 E09.3593 E09.3599** Unspecified diabetic retinopathy without macular edema **E09.319** Type 1 diabetes mellitus with... **Right eye** Left eye Bilateral Unspecified eye Mild nonproliferative diabetic retinopathy without macular edema E10.3291 E10.3292 E10.3293 E10.3299 Moderate nonproliferative diabetic retinopathy without macular edema E10.3391 E10.3392 E10.3393 E10.3399 Severe nonproliferative diabetic retinopathy without macular edema E10.3491 E10.3492 E10.3493 E10.3499 Proliferative diabetic retinopathy without macular edema E10.3591 E10.3592 E10.3593 E10.3599 Unspecified diabetic retinopathy without macular edema E10.319 Type 2 diabetes mellitus with... **Right eye** Left eye Bilateral Unspecified eye 🗆 E11.3291 Mild nonproliferative diabetic retinopathy without macular edema E11.3292 E11.3293 E11.3299 Moderate nonproliferative diabetic retinopathy without macular edema E11.3393 E11.3391 E11.3392 E11.3399 Severe nonproliferative diabetic retinopathy without macular edema E11.3491 E11.3492 E11.3493 E11.3499 Stable proliferative diabetic retinopathy E11.3551 E11.3552 E11.3553 E11.3559 E11.3592 E11.3593 Proliferative diabetic retinopathy without macular edema E11.3591 E11.3599 🗆 E11.319 Unspecified diabetic retinopathy without macular edema Other specified diabetes mellitus with... **Right eye** Left eye Bilateral Unspecified eye Mild nonproliferative diabetic retinopathy without macular edema E13.3291 E13.3292 E13.3293 E13.3299 Moderate nonproliferative diabetic retinopathy without macular edema E13.3391 E13.3392 E13.3393 E13.3399 Severe nonproliferative diabetic retinopathy without macular edema 🗆 E13.3491 E13.3492 E13.3493 E13.3499 Proliferative diabetic retinopathy without macular edema E13.3591 E13.3592 E13.3593 E13.3599 Unspecified diabetic retinopathy without macular edema E13.319 □ Other (only available for PAP). Visual Acuity: Right Eye: _ Has patient started treatment? Ves No Left Eye: Anticipated date of treatment: **Secondary and Tertiary Diagnoses**

Patient Name		
First Name:	Middle Initial: Last Name:	
Preferred Language: 🗆 English	🗆 Spanish	□ Other:

Section 6.1: Authorization to Disclose/Use Health Information

I authorize my health care providers and staff, my health insurer, health plan or programs that provide me health care benefits (together, "Health Insurers") and any specialty pharmacy(s) that dispense my medication to disclose to Regeneron Pharmaceuticals, Inc. and its affiliates, representatives, agents and contractors (together, "Regeneron") health information about me, including information related to my medical condition, treatment with EYLEA® (aflibercept) Injection, health insurance coverage, claims, prescription, and referral to and enrollment in the EYLEA4U® Programs (together, "My Information"). My health care providers, Health Insurers, specialty pharmacy(s) and Regeneron may use and disclose My Information for the purposes of providing certain support services, including:

- to determine if I am eligible to participate in Regeneron's reimbursement and coverage assistance program(s), patient assistance programs and other support programs (together, "EYLEA4U Programs");
- for the operation and administration of the EYLEA4U Programs;
- to investigate my health insurance coverage benefits;
- to obtain prior authorization for coverage/reimbursement;
- to assist with appeals of denied claims for coverage/reimbursement; and
- to refer me to, or to determine my eligibility for, other programs, foundations or alternate sources of funding or coverage that may be available to provide assistance to me with the costs of my medications.

I understand and agree that my health care providers, Health Insurers and specialty pharmacy(s) may receive remuneration from Regeneron in exchange for disclosing My Information to Regeneron and/or for providing me with support services in connection with EYLEA or the EYLEA4U Programs. Once My Information has been disclosed to Regeneron, I understand that federal privacy laws may no longer protect it from further disclosure. However, Regeneron agrees to protect My Information by using and disclosing it only for the purposes authorized in this Authorization or as otherwise required by law.

I understand that if I refuse to sign this Authorization, I will not be able to participate in the EYLEA4U Programs, but it will not affect my eligibility to obtain medical treatment, my ability to seek payment for this treatment or affect my insurance enrollment or eligibility for insurance coverage.

Further, I understand that I may withdraw (take back) this Authorization at any time by mailing or faxing a written request to Regeneron at P.O. Box 220578, Charlotte, NC 28222-0578; Fax: (888) 335-3264. Withdrawal of this Authorization will end further uses and disclosures of My Information by the parties identified in this Authorization except to the extent those uses and disclosures have been made in reliance upon this Authorization. This Authorization expires 18 months from the date support is last provided under any EYLEA4U Program, subject to applicable law, unless I withdraw it earlier. I understand that I may request a copy of this Authorization.

Section 6.2: Financial Information (must be completed for PAP requests)

How many people live in your household? _

Total Annual Household Income (including salary/wages; Social Security income; disability income; any other income):*\$0 to \$100,000\$100,001 to \$150,000Greater than \$150,000

*Supporting documentation will be required. EYLEA4U may also ask for proof of income at any time for audit/verification.

Please complete this application and submit by fax to 1-888-335-3264 or retain completed and patient-signed form on file at your office if submission is entered via the e-Portal.

Patient Name			
First Name:		Middle Init	tial: Last Name:
Preferred Lang	uage: 🗆 English	🗆 Spanish	Other:

Section 6.3: Patient Certification

By signing, I am enrolling in the EYLEA4U[®] Programs, and authorize Regeneron to provide me with the EYLEA4U Programs. I verify that the information on this application and other supporting documentation is complete and accurate. I also verify that unless I have identified otherwise in this application, I have no other coverage for prescription medications, including Medicaid, Medicare or any public or private assistance programs, or any other form of insurance.

I also agree that Regeneron may verify my eligibility for the EYLEA4U Programs, and I understand that such verification may include contacting me or my health care provider for additional information and/or reviewing additional financial, insurance, and/or medical information. I authorize Regeneron to use my Social Security number and/or additional demographic information to access reports on my individual credit history from consumer reporting agencies. I understand that upon request, Regeneron will tell me whether an individual consumer report was requested and the name and address of the agency that furnished it. I further understand and authorize Regeneron to use any consumer reports about me and information collected from me, along with other information they obtain from public and other sources to estimate my income in conjunction with the patient assistance program eligibility determination process, if applicable.

I authorize Regeneron to contact me by mail, telephone, or email, with information about the EYLEA4U Programs, FDA-approved indications of EYLEA® (aflibercept) Injection, related disease state information and products, promotions, services and research studies, and to ask my opinion about such information and topics, including market research and disease-related surveys. I further authorize Regeneron to de-identify my health information and use it in performing research, education, business analytics, marketing studies or for other commercial purposes. I understand that members of Regeneron may share identifiable health information with one another in order to de-identify it for these purposes and as needed to perform the EYLEA4U Programs or to send the communications listed above (the "Communications"). I understand and agree that Regeneron may use my health information for these purposes and may share my health information with my doctors, specialty pharmacies, and insurers.

In connection with administering the EYLEA4U Programs, I understand that Regeneron may contact me or my health care provider directly to confirm receipt of medications or to provide other information related to the EYLEA4U Programs. I also understand that Regeneron may revise, change or terminate the EYLEA4U Programs at any time.

I understand that I do not have to enroll in the EYLEA4U Programs or receive the Communications, and that I can still receive EYLEA as prescribed by my physician. I may opt out of receiving Communications, individual programs offered by the EYLEA4U Programs or opt out of the EYLEA4U Programs entirely at any time by mailing or faxing a written request to Regeneron at P.O. Box 220578, Charlotte, NC 28222-0578; Fax: (888) 335-3264.

Please complete this application and submit by fax to 1-888-335-3264 or retain completed and patient-signed form on file at your office if submission is entered via the e-Portal.

EYLEA and EYLEA4U are registered trademarks of Regeneron Pharmaceuticals, Inc.

REGENERON